BMS registers new deucravacitinib continuation study; prior week's trial results still standAug 27Weekly roundup, 5 itemsBristol Myers Squibbdeucravacitinib
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106Aug 13Quarterly updateInhibrx Biosciences, Inc
Sign inSign in